{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T12:36:41Z","timestamp":1794573401899,"version":"4.9.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-64861-6","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:34:42Z","timestamp":1762864482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Engineered CXCR3-A expression enhances B7-H3-targeting CAR T cell migration and efficacy against diffuse intrinsic pontine glioma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4022-9753","authenticated-orcid":false,"given":"Edward Z.","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Timpanaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2710-606X","authenticated-orcid":false,"given":"Michael","family":"Meechan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonel","family":"Elena-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4616-736X","authenticated-orcid":false,"given":"Lucy Z.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Jamet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3744-868X","authenticated-orcid":false,"given":"Davina S.","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-3868-3284","authenticated-orcid":false,"given":"Lily I.","family":"Winter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9063-5370","authenticated-orcid":false,"given":"Matthew D.","family":"Dun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8001-5960","authenticated-orcid":false,"given":"Jessica B.","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myron K.","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan S.","family":"Pattwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Kalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surojit","family":"Sarkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6152-3604","authenticated-orcid":false,"given":"Matthew C.","family":"Biery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3966-4985","authenticated-orcid":false,"given":"Nicholas A.","family":"Vitanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"64861_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"64861_CR2","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/neuonc\/nox107","volume":"19","author":"T Cooney","year":"2017","unstructured":"Cooney, T. et al. Contemporary survival endpoints: an International Diffuse Intrinsic Pontine Glioma Registry study. Neuro Oncol. 19, 1279\u20131280 (2017).","journal-title":"Neuro Oncol."},{"key":"64861_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1007\/s11940-019-0577-y","volume":"21","author":"NA Vitanza","year":"2019","unstructured":"Vitanza, N. A. & Monje, M. Diffuse intrinsic pontine glioma: from diagnosis to next-generation clinical trials. Curr. Treat. Options Neurol. 21, 37 (2019).","journal-title":"Curr. Treat. Options Neurol."},{"key":"64861_CR4","doi-asserted-by":"publisher","unstructured":"Ronsley, R. et al. CAR T cell therapy for pediatric central nervous system tumors: a review of the literature and current North American trials. Cancer Metastasis Rev https:\/\/doi.org\/10.1007\/s10555-024-10208-4 (2024).","DOI":"10.1007\/s10555-024-10208-4"},{"key":"64861_CR5","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/2159-8290.CD-24-1465","volume":"15","author":"A Timpanaro","year":"2025","unstructured":"Timpanaro, A. et al. Evolving CAR T-cell therapy to overcome the barriers in treating pediatric central nervous system tumors. Cancer Discov. 15, 890\u2013902 (2025).","journal-title":"Cancer Discov."},{"key":"64861_CR6","doi-asserted-by":"publisher","unstructured":"Uslu, U. & June, C. H. Beyond the blood: expanding CAR T cell therapy to solid tumors. Nat. Biotechnol. https:\/\/doi.org\/10.1038\/s41587-024-02446-2 (2024).","DOI":"10.1038\/s41587-024-02446-2"},{"key":"64861_CR7","doi-asserted-by":"publisher","unstructured":"Ferreras, C. et al. Facing CAR T cell challenges on the deadliest paediatric brain tumours. Cells 10 https:\/\/doi.org\/10.3390\/cells10112940 (2021).","DOI":"10.3390\/cells10112940"},{"key":"64861_CR8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1158\/2159-8290.CD-22-0750","volume":"13","author":"NA Vitanza","year":"2023","unstructured":"Vitanza, N. A. et al. Intraventricular B7-H3 CAR T cells for diffuse intrinsic pontine glioma: preliminary first-in-human bioactivity and safety. Cancer Discov. 13, 114\u2013131 (2023).","journal-title":"Cancer Discov."},{"key":"64861_CR9","doi-asserted-by":"publisher","unstructured":"Vitanza, N. A. et al. Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-024-03451-3 (2025).","DOI":"10.1038\/s41591-024-03451-3"},{"key":"64861_CR10","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1084\/jem.184.3.963","volume":"184","author":"M Loetscher","year":"1996","unstructured":"Loetscher, M. et al. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 184, 963\u2013969 (1996).","journal-title":"J. Exp. Med."},{"key":"64861_CR11","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1002\/(SICI)1521-4141(199811)28:11<3696::AID-IMMU3696>3.0.CO;2-W","volume":"28","author":"M Loetscher","year":"1998","unstructured":"Loetscher, M., Loetscher, P., Brass, N., Meese, E. & Moser, B. Lymphocyte-specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization. Eur. J. Immunol. 28, 3696\u20133705 (1998).","journal-title":"Eur. J. Immunol."},{"key":"64861_CR12","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/blood-2002-12-3945","volume":"102","author":"MJ Smit","year":"2003","unstructured":"Smit, M. J. et al. CXCR3-mediated chemotaxis of human T cells is regulated by a Gi- and phospholipase C-dependent pathway and not via activation of MEK\/p44\/p42 MAPK nor Akt\/PI-3 kinase. Blood 102, 1959\u20131965 (2003).","journal-title":"Blood"},{"key":"64861_CR13","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1111\/j.1365-2567.2010.03384.x","volume":"132","author":"A Korniejewska","year":"2011","unstructured":"Korniejewska, A., McKnight, A. J., Johnson, Z., Watson, M. L. & Ward, S. G. Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes. Immunology 132, 503\u2013515 (2011).","journal-title":"Immunology"},{"key":"64861_CR14","doi-asserted-by":"publisher","unstructured":"Reynders, N. et al. The distinct roles of CXCR3 variants and their ligands in the tumor microenvironment. Cells 8 https:\/\/doi.org\/10.3390\/cells8060613 (2019).","DOI":"10.3390\/cells8060613"},{"key":"64861_CR15","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3389\/fimmu.2020.00976","volume":"11","author":"N Karin","year":"2020","unstructured":"Karin, N. CXCR3 ligands in cancer and autoimmunity, chemoattraction of effector T cells, and beyond. Front Immunol. 11, 976 (2020).","journal-title":"Front Immunol."},{"key":"64861_CR16","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.4049\/jimmunol.158.7.3046","volume":"158","author":"WE Biddison","year":"1997","unstructured":"Biddison, W. E. et al. Chemokine and matrix metalloproteinase secretion by myelin proteolipid protein-specific CD8+ T cells: potential roles in inflammation. J. Immunol. 158, 3046\u20133053 (1997).","journal-title":"J. Immunol."},{"key":"64861_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-11869-4","volume":"10","author":"L Jin","year":"2019","unstructured":"Jin, L. et al. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat. Commun. 10, 4016 (2019).","journal-title":"Nat. Commun."},{"key":"64861_CR18","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/CJI.0b013e3181ee6675","volume":"33","author":"JA Craddock","year":"2010","unstructured":"Craddock, J. A. et al. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J. Immunother. 33, 780\u2013788 (2010).","journal-title":"J. Immunother."},{"key":"64861_CR19","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/s41551-021-00737-6","volume":"5","author":"S Lesch","year":"2021","unstructured":"Lesch, S. et al. T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nat. Biomed. Eng. 5, 1246\u20131260 (2021).","journal-title":"Nat. Biomed. Eng."},{"key":"64861_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29647-0","volume":"13","author":"H Li","year":"2022","unstructured":"Li, H. et al. Targeting brain lesions of non-small cell lung cancer by enhancing CCL2-mediated CAR-T cell migration. Nat. Commun. 13, 2154 (2022).","journal-title":"Nat. Commun."},{"key":"64861_CR21","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/eji.201948457","volume":"50","author":"G Liu","year":"2020","unstructured":"Liu, G. et al. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Eur. J. Immunol. 50, 712\u2013724 (2020).","journal-title":"Eur. J. Immunol."},{"key":"64861_CR22","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.1158\/1078-0432.CCR-11-0351","volume":"17","author":"EK Moon","year":"2011","unstructured":"Moon, E. K. et al. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin. Cancer Res. 17, 4719\u20134730 (2011).","journal-title":"Clin. Cancer Res."},{"key":"64861_CR23","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1016\/j.ymthe.2023.09.010","volume":"31","author":"R Sun","year":"2023","unstructured":"Sun, R. et al. CXCR4-modified CAR-T cells suppresses MDSCs recruitment via STAT3\/NF-kappaB\/SDF-1alpha axis to enhance efficacy against pancreatic cancer. Mol. Ther. 31, 3193\u20133209 (2023).","journal-title":"Mol. Ther."},{"key":"64861_CR24","doi-asserted-by":"publisher","first-page":"628906","DOI":"10.3389\/fimmu.2021.628906","volume":"12","author":"Y Wang","year":"2021","unstructured":"Wang, Y. et al. Chemokine Receptor CCR2b enhanced anti-tumor function of chimeric antigen Receptor T cells targeting mesothelin in a non-small-cell lung carcinoma model. Front Immunol. 12, 628906 (2021).","journal-title":"Front Immunol."},{"key":"64861_CR25","doi-asserted-by":"publisher","unstructured":"Whilding, L. M. et al. CAR T-cells targeting the Integrin \u03b1v\u03b26 and Co-Expressing the Chemokine Receptor CXCR2 demonstrate enhanced homing and efficacy against several solid malignancies. Cancers 11 https:\/\/doi.org\/10.3390\/cancers11050674 (2019).","DOI":"10.3390\/cancers11050674"},{"key":"64861_CR26","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","volume":"27","author":"NA Vitanza","year":"2021","unstructured":"Vitanza, N. A. et al. Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis. Nat. Med. 27, 1544\u20131552 (2021).","journal-title":"Nat. Med."},{"key":"64861_CR27","doi-asserted-by":"publisher","first-page":"7080","DOI":"10.18632\/oncotarget.27389","volume":"10","author":"AC Ravanpay","year":"2019","unstructured":"Ravanpay, A. C. et al. EGFR806-CAR T cells selectively target a tumor-restricted EGFR epitope in glioblastoma. Oncotarget 10, 7080\u20137095 (2019).","journal-title":"Oncotarget"},{"key":"64861_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100870","volume":"36","author":"NA Vitanza","year":"2023","unstructured":"Vitanza, N. A. et al. Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety. Neoplasia 36, 100870 (2023).","journal-title":"Neoplasia"},{"key":"64861_CR29","first-page":"148","volume":"14","author":"NA Vitanza","year":"2024","unstructured":"Vitanza, N. A. et al. Locoregional CAR T cells for the treatment of CNS tumors in children: investigational drug service pharmacy activities. J. Hematol. Oncol. Pharm. 14, 148\u2013154 (2024).","journal-title":"J. Hematol. Oncol. Pharm."},{"key":"64861_CR30","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/neuonc\/noaa278","volume":"23","author":"D Haydar","year":"2021","unstructured":"Haydar, D. et al. Cell-surface antigen profiling of pediatric brain tumors: B7-H3 is consistently expressed and can be targeted via local or systemic CAR T-cell delivery. Neuro Oncol. 23, 999\u20131011 (2021).","journal-title":"Neuro Oncol."},{"key":"64861_CR31","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","volume":"25","author":"RG Majzner","year":"2019","unstructured":"Majzner, R. G. et al. CAR T cells targeting B7-H3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors. Clin. Cancer Res 25, 2560\u20132574 (2019).","journal-title":"Clin. Cancer Res"},{"key":"64861_CR32","first-page":"158","volume":"1","author":"MC Biery","year":"2020","unstructured":"Biery, M. C. et al. A Protocol for the generation of treatment-naive biopsy-derived diffuse intrinsic pontine glioma and diffuse midline glioma models. J. Exp. Neurol. 1, 158\u2013167 (2020).","journal-title":"J. Exp. Neurol."},{"key":"64861_CR33","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1084\/jem.166.4.1084","volume":"166","author":"AD Luster","year":"1987","unstructured":"Luster, A. D. & Ravetch, J. V. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J. Exp. Med. 166, 1084\u20131097 (1987).","journal-title":"J. Exp. Med."},{"key":"64861_CR34","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","volume":"24","author":"CW Mount","year":"2018","unstructured":"Mount, C. W. et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M(+) diffuse midline gliomas. Nat. Med. 24, 572\u2013579 (2018).","journal-title":"Nat. Med."},{"key":"64861_CR35","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1172\/JCI83416","volume":"126","author":"M Hegde","year":"2016","unstructured":"Hegde, M. et al. Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J. Clin. Invest. 126, 3036\u20133052 (2016).","journal-title":"J. Clin. Invest."},{"key":"64861_CR36","volume":"5","author":"A Schmidts","year":"2023","unstructured":"Schmidts, A. et al. Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Ralpha2 are effective against heterogeneous glioblastoma. Neurooncol. Adv. 5, vdac185 (2023).","journal-title":"Neurooncol. Adv."},{"key":"64861_CR37","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.omto.2022.02.012","volume":"24","author":"N Muhammad","year":"2022","unstructured":"Muhammad, N. et al. A novel TanCAR targeting IL13Ralpha2 and EphA2 for enhanced glioblastoma therapy. Mol. Ther. Oncol. 24, 729\u2013741 (2022).","journal-title":"Mol. Ther. Oncol."},{"key":"64861_CR38","doi-asserted-by":"publisher","first-page":"7622","DOI":"10.7150\/thno.43991","volume":"10","author":"M Yang","year":"2020","unstructured":"Yang, M. et al. Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors. Theranostics 10, 7622\u20137634 (2020).","journal-title":"Theranostics"},{"key":"64861_CR39","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley, S. J. et al. Intrathecal bivalent CAR T cells targeting EGFR and IL13Ralpha2 in recurrent glioblastoma: phase 1 trial interim results. Nat. Med 30, 1320\u20131329 (2024).","journal-title":"Nat. Med"},{"key":"64861_CR40","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/neuonc\/nox182","volume":"20","author":"K Bielamowicz","year":"2018","unstructured":"Bielamowicz, K. et al. Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol. 20, 506\u2013518 (2018).","journal-title":"Neuro Oncol."},{"key":"64861_CR41","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/s41591-020-0827-2","volume":"26","author":"LK Donovan","year":"2020","unstructured":"Donovan, L. K. et al. Locoregional delivery of CAR T cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma. Nat. Med 26, 720\u2013731 (2020).","journal-title":"Nat. Med"},{"key":"64861_CR42","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","volume":"37","author":"BD Choi","year":"2019","unstructured":"Choi, B. D. et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat. Biotechnol. 37, 1049\u20131058 (2019).","journal-title":"Nat. Biotechnol."},{"key":"64861_CR43","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","volume":"390","author":"BD Choi","year":"2024","unstructured":"Choi, B. D. et al. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma. N. Engl. J. Med 390, 1290\u20131298 (2024).","journal-title":"N. Engl. J. Med"},{"key":"64861_CR44","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.omto.2022.11.004","volume":"27","author":"EZ Song","year":"2022","unstructured":"Song, E. Z. et al. The IAP antagonist birinapant enhances chimeric antigen receptor T cell therapy for glioblastoma by overcoming antigen heterogeneity. Mol. Ther. Oncol. 27, 288\u2013304 (2022).","journal-title":"Mol. Ther. Oncol."},{"key":"64861_CR45","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s40478-018-0553-x","volume":"6","author":"GL Lin","year":"2018","unstructured":"Lin, G. L. et al. Non-inflammatory tumor microenvironment of diffuse intrinsic pontine glioma. Acta Neuropathol. Commun. 6, 51 (2018).","journal-title":"Acta Neuropathol. Commun."},{"key":"64861_CR46","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1093\/neuonc\/noy145","volume":"21","author":"NAP Lieberman","year":"2019","unstructured":"Lieberman, N. A. P. et al. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy. Neuro Oncol. 21, 83\u201394 (2019).","journal-title":"Neuro Oncol."},{"key":"64861_CR47","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/S0165-5728(03)00009-2","volume":"136","author":"G Flynn","year":"2003","unstructured":"Flynn, G., Maru, S., Loughlin, J., Romero, I. A. & Male, D. Regulation of chemokine receptor expression in human microglia and astrocytes. J. Neuroimmunol. 136, 84\u201393 (2003).","journal-title":"J. Neuroimmunol."},{"key":"64861_CR48","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1128\/JVI.77.8.4502-4515.2003","volume":"77","author":"MC Cheeran","year":"2003","unstructured":"Cheeran, M. C., Hu, S., Sheng, W. S., Peterson, P. K. & Lokensgard, J. R. CXCL10 production from cytomegalovirus-stimulated microglia is regulated by both human and viral interleukin-10. J. Virol. 77, 4502\u20134515 (2003).","journal-title":"J. Virol."},{"key":"64861_CR49","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1089\/jir.2006.0157","volume":"27","author":"X Wang","year":"2007","unstructured":"Wang, X. & Suzuki, Y. Microglia produce IFN-gamma independently from T cells during acute toxoplasmosis in the brain. J. Interferon Cytokine Res. 27, 599\u2013605 (2007).","journal-title":"J. Interferon Cytokine Res."},{"key":"64861_CR50","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.ymthe.2022.08.021","volume":"31","author":"G Wang","year":"2023","unstructured":"Wang, G. et al. CXCL11-armed oncolytic adenoviruses enhance CAR-T cell therapeutic efficacy and reprogram tumor microenvironment in glioblastoma. Mol. Ther. 31, 134\u2013153 (2023).","journal-title":"Mol. Ther."},{"key":"64861_CR51","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ymthe.2017.10.002","volume":"26","author":"CE Brown","year":"2018","unstructured":"Brown, C. E. et al. Optimization of IL13Ralpha2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma. Mol. Ther. 26, 31\u201344 (2018).","journal-title":"Mol. Ther."},{"key":"64861_CR52","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","volume":"26","author":"J Theruvath","year":"2020","unstructured":"Theruvath, J. et al. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors. Nat. Med 26, 712\u2013719 (2020).","journal-title":"Nat. Med"},{"key":"64861_CR53","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","volume":"6","author":"S Ghassemi","year":"2022","unstructured":"Ghassemi, S. et al. Rapid manufacturing of non-activated potent CAR T cells. Nat. Biomed. Eng. 6, 118\u2013128 (2022).","journal-title":"Nat. Biomed. Eng."},{"key":"64861_CR54","doi-asserted-by":"publisher","unstructured":"Mishra, H. K. & Kalyuzhny, A. Revolutionizing cancer treatments through stem cell-derived CAR T Cells for immunotherapy: opening new horizons for the future of oncology. Cells 13 https:\/\/doi.org\/10.3390\/cells13181516 (2024).","DOI":"10.3390\/cells13181516"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64861-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64861-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64861-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:04:06Z","timestamp":1762869846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64861-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["64861"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-64861-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6272325\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"28 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.Z.S., M.C.J. and N.A.V. are inventors on pending patents related to this study, which are disclosed in U.S. Provisional Patent Application No. 63\/569,626, entitled \u201cCXCR3-ENGINEERED ANTI-B7H3 CAR T CELLS\u201d, U.S. Provisional Patent Application No. 63\/653,023, entitled \u201cCXCR3 ISOFORMS TO IMPROVE ANTI-B7-H3 RECOMBINANT RECEPTOR TRAFFICKING\u201d, and International Patent Application No. PCT\/US2025\/021354, entitled \u201cCXCR3 ISOFORMS TO IMPROVE RECOMBINANT RECEPTOR TRAFFICKING\u201d. M.C.J. holds equity in and is the Chief Scientific Officer of BrainChild Bio, Inc. M.C.J. holds equity in, is a Board Observer for and serves as a member of the Joint Steering Committee of Umoja Biopharma, Inc. N.A.V. holds equity in and serves as the Scientific Advisory Board Chair for BrainChild Bio, Inc. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9914"}}